Immunome Analyst Price Targets - Benzinga

Immunome Inc

IMNMNASDAQ

Trade with Public

Trade with Public

$18.29

0.372.06%

Dern. MÀJ: Oct 21, 10:42 AM

$17.99

0.070.39%

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Options Rapport sur les stocks

Immunome Analyst Price Targets - Benzinga

Immunome Analyst Price Targets

Wall Street analyst price targets and consensus rating for Immunome (IMNM).

Price Target Range — 13 Quarters

Analyst Consensus — 17 Analysts

16Buy

1Hold

Consensus RatingBuy# Analysts17Avg. Consensus PT$32Upside to Avg. PT+72.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 16, 2026	William Blair	Alethia Young	Initiate	Outperform	—
Oct 1, 2026	Stifel	Dara Azar	Initiate	Hold	$24
Sep 21, 2026	Alliance Global Partners	Matthew Venezia	Initiate	Buy	$32
Sep 10, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$40
Aug 12, 2026	Truist Securities	Supawat Thongthip	PT Raise	Buy	$37→$38
Aug 12, 2026	Wedbush	David Nierengarten	PT Raise	Outperform	$31→$35
Jul 21, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$31
Jun 12, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$31
May 28, 2026	Truist Securities	Supawat Thongthip	PT Raise	Buy	$36→$37
May 28, 2026	Barclays	Lukas Shumway	Initiate	Overweight	$36
May 15, 2026	Leerink Partners	Andrew Berens	PT Cut	Outperform	$37→$33
May 13, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Maintained	Buy	$40
Mar 4, 2026	Craig-Hallum	Adam Vogel	PT Raise	Buy	$33→$36
Mar 4, 2026	Stephens & Co.	Sudan Loganathan	PT Cut	Overweight	$33→$30
Feb 12, 2026	HC Wainwright & Co.	Andres Y. Maldonado	Initiate	Buy	$40
Jan 15, 2026	Wedbush	David Nierengarten	Maintained	Outperform	$31
Dec 16, 2025	Lake Street	Chad Messer	PT Raise	Buy	$22→$32
Dec 16, 2025	Evercore ISI Group	Cory Kasimov	PT Raise	Outperform	$18→$40
Dec 16, 2025	Guggenheim	Michael Schmidt	PT Raise	Buy	$25→$35
Dec 1, 2025	Truist Securities	Karina Rabayeva	Initiate	Buy	$36

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
William Blair Initiates Coverage On Immunome with Outperform Rating

William Blair analyst Alethia Young initiates coverage on Immunome (NASDAQ:IMNM) with a Outperform rating.

Benzinga Newsdesk

PRO
Stifel Initiates Coverage On Immunome with Hold Rating, Announces Price Target of $24

Stifel analyst Dara Azar initiates coverage on Immunome (NASDAQ:IMNM) with a Hold rating and announces Price Target of $24.

Benzinga Newsdesk

PRO
Alliance Global Partners Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $32

Alliance Global Partners analyst Matthew Venezia initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of $32.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Immunome, Maintains $40 Price Target

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Immunome (NASDAQ:IMNM) with a Buy and maintains $40 price target.

Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on Immunome, Raises Price Target to $38

Truist Securities analyst Supawat Thongthip maintains Immunome (NASDAQ:IMNM) with a Buy and raises the price target from $37 to $38.

Benzinga Newsdesk

PRO
Wedbush Maintains Outperform on Immunome, Raises Price Target to $35

Wedbush analyst David Nierengarten maintains Immunome (NASDAQ:IMNM) with a Outperform and raises the price target from $31 to $35.

Benzinga Newsdesk